Published in Thromb Haemost on February 01, 1998
A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood (2007) 1.22
Effect of maternal anti-HPA-1a antibodies and polyclonal IVIG on the activation status of vascular endothelial cells. Clin Exp Immunol (2004) 0.82
Quantitative Influence of ABO Blood Groups on Factor VIII and Its Ratio to von Willebrand Factor, Novel Observations from an ARIC Study of 11,673 Subjects. PLoS One (2015) 0.82
Increased risk of venous thrombosis by AB alleles of the ABO blood group and Factor V Leiden in a Brazilian population. Genet Mol Biol (2009) 0.81
High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature. Medicine (Baltimore) (2013) 0.79
Genetic variations in sites of affinity between FVIII and LRP1 are not associated with high FVIII levels in venous thromboembolism. Sci Rep (2015) 0.75
Association of Single Nucleotide Polymorphisms in the ST3GAL4 Gene with VWF Antigen and Factor VIII Activity. PLoS One (2016) 0.75
Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature (1994) 9.06
The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA (1995) 7.31
Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet (1994) 5.58
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
Oral contraceptives and the risk of myocardial infarction. N Engl J Med (2001) 5.18
Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med (1995) 5.16
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet (1995) 5.10
End of the line for "third-generation-pill" controversy? Lancet (1997) 4.63
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ (2009) 4.18
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med (1996) 4.11
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet (1995) 4.01
Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation (1994) 3.65
Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost (2006) 3.49
Increased fetal loss in women with heritable thrombophilia. Lancet (1996) 3.34
Is publication bias a medical problem? Lancet (1993) 3.04
Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost (2006) 3.03
Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc (1999) 2.71
Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med (1993) 2.70
Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med (1996) 2.63
Oral contraceptives and the risk of venous thrombosis. N Engl J Med (2001) 2.57
Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet (2005) 2.45
High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med (2000) 2.39
Antipsychotic medication and venous thrombosis. Br J Psychiatry (2001) 2.37
Atomic force microscopy: a novel approach to the detection of nanosized blood microparticles. J Thromb Haemost (2009) 2.33
Activation of coagulation system during air travel: a crossover study. Lancet (2006) 2.32
Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost (2012) 2.30
Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation (1998) 2.26
Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA (1999) 2.21
Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients. J Thromb Haemost (2012) 2.17
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost (2005) 2.13
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ (1996) 2.11
Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study) Blood (1995) 2.09
Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost (2008) 2.06
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost (2006) 2.06
Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost (1999) 2.04
Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med (1983) 2.03
The family history and inherited thrombophilia. Br J Haematol (1994) 2.03
Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost (2006) 2.01
Seasonal variation of venous thrombosis: a consecutive case series within studies from Leiden, Milan and Tromsø. J Thromb Haemost (2012) 2.01
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet (1995) 2.00
Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands. Lancet (1996) 1.99
The putative factor IX gene promoter in hemophilia B Leyden. Blood (1988) 1.98
Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet (1993) 1.96
Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med (1999) 1.95
Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial. Kidney Int (2006) 1.92
Power of selective genotyping in genetic association analyses of quantitative traits. Behav Genet (2000) 1.89
Octapeptide repeat insertions in the prion protein gene and early onset dementia. J Neurol Neurosurg Psychiatry (2004) 1.87
Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut (2001) 1.86
Second-generation recombinant factor VIII and inhibitor risk: interpretation of RODIN study findings and implications for patients with haemophilia A. Haemophilia (2013) 1.84
von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost (2006) 1.84
Testing the fit of a regression model via score tests in random effects models. Biometrics (1995) 1.76
The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol (1996) 1.76
Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet (2003) 1.76
Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg (1994) 1.74
Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost (2005) 1.73
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol (2000) 1.72
Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet (2001) 1.71
Course of the international Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br J Haematol (1999) 1.69
Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann Rheum Dis (2012) 1.68
The Leiden Thrombophilia Study (LETS). Thromb Haemost (1997) 1.65
Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A) Stroke (1998) 1.63
Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in the Netherlands. Diabetologia (2002) 1.63
Usefulness of patient interview in bleeding disorders. Arch Intern Med (1995) 1.62
High levels of factor IX increase the risk of venous thrombosis. Blood (2000) 1.61
Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer (2013) 1.60
Nucleotide sequence of a cDNA for a member of the human 90-kDa heat-shock protein family. Gene (1987) 1.60
Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol (1997) 1.59
Cerebral haemorrhagic infarction in young patients with hereditary protein C deficiency: evidence for "spontaneous" cerebral venous thrombosis. Br Med J (Clin Res Ed) (1985) 1.58
Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost (1996) 1.58
Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost (2008) 1.57
Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann Rheum Dis (2012) 1.56
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost (2012) 1.56
The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost (2003) 1.55
Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost (2007) 1.55
Proof of principle of potential clinical utility of multiple SNP analysis for prediction of recurrent venous thrombosis. J Thromb Haemost (2008) 1.53
Hereditary protein S deficiency: clinical manifestations. Ann Intern Med (1987) 1.53
Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia (2010) 1.51
Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol (2000) 1.51
The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost (2004) 1.49